CSIMarket
 
Tcr2 Therapeutics Inc   (TCRR)
Other Ticker:  
 

Tcr2 Therapeutics Inc

Business Description


TCR2 Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, with a focus on developing novel T-cell therapies for the treatment of cancer. The company was founded in 2015 by a team of scientists and researchers with extensive experience in immunology and cancer biology.

At the core of TCR2*s technology is its proprietary T-cell Receptor Fusion Construct (TRuC) platform. The TRuC platform is designed to enhance the natural ability of T-cells to recognize and destroy cancer cells. It combines the benefits of chimeric antigen receptors (CARs) and T-cell receptors (TCRs) into a single molecule to effectively target a wider range of tumor antigens.

Unlike traditional CAR-T therapies, which predominantly target surface antigens, TCR2*s TRuC-T cells are engineered to recognize intracellular proteins. This enables them to target a broader spectrum of tumors that express both surface and intracellular antigens, making it a potentially powerful tool in treating solid tumors, which have been historically challenging to target using immunotherapies.

TCR2 has developed a unique approach for manufacturing TRuC-T cells called TRuC-T-cell Process (TRuC-T). This process uses a lentiviral vector system to efficiently deliver the TRuC construct into patient-derived T-cells. Once infused into the patient, TRuC-T cells are intended to recognize and eliminate cancer cells expressing the target antigen.

The company has a robust pipeline of product candidates in various stages of development. Its lead program, TC-210, is being evaluated in a Phase 1/2 clinical trial in patients with advanced mesothelin-expressing solid tumors. TC-210 has shown promising preclinical data, demonstrating its ability to induce tumor regression and enhance antitumor immunity.

In addition to TC-210, TCR2 is also developing other TRuC-T cell therapies targeting solid tumors, including TC-110 for CD19-positive hematological malignancies and TC-220 for MUC16-positive ovarian cancer. The company is actively engaged in preclinical research and development to expand its TRuC platform into additional cancer indications.

TCR2 Therapeutics has a strong intellectual property portfolio, with multiple issued patents covering its TRuC platform and related technologies. The company has also entered into collaborations with other leading biopharmaceutical companies, aiming to leverage their expertise and resources to accelerate the development and commercialization of its TRuC-T cell therapies.

Overall, TCR2 Therapeutics Inc. is a cutting-edge biotech company at the forefront of T-cell therapy research, leveraging its innovative TRuC platform to develop potentially transformative treatments for cancer.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com